Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ViroPharma Talks Cinryze Sales, EU Launches

This article was originally published in The Pink Sheet Daily

Executive Summary

ViroPharma assures investors that its lead product Cinryze is growing and that launches in the EU are on track during an analyst day presentation.

You may also be interested in...



Shire’s ViroPharma Purchase Aims To Build Rare Disease Giant

Shire is buying ViroPharma at a steep premium to acquire its pipeline assets, notably C1 esterase inhibitor Cinryze, which the London-listed specialty pharma plans to expand internationally, initially to treat hereditary angioedema and later for other rare diseases.

Shire Buying ViroPharma To Create Leading Rare Disease Group

Shire is snapping up ViroPharma at a hefty premium to secure possession of C1 esterase inhibitor Cinryze and position the group as a formidable force in treatments for rare diseases.

Salix Acquires Santarus: Synergies And Analyst Sentiment

Some analysts balked, but Salix management defended the price the company is paying for Santarus on a Nov. 7 earnings call, arguing that synergies from an integration support the valuation of six to seven times the sales price.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS074688

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel